NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, announced today that Mai-Britt Zocca, PhD, the company’s President and CEO, along with Amy Sullivan, the company’s CFO, and Qasim Ahmad, MD, the company’s CMO, will be participating in a fireside chat at the TD Cowen 6 th Annual... Read More

Primary endpoint of pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine in patients with advanced melanoma still expected to readout in third quarter of 2025 Data presented at recent congresses reinforces the potential of the company’s T-Win candidates to reshape the tumor microenvironment and drive more effective anti-tumor responses Company recognized as one of the most innovative... Read More

NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that one of its scientific co-founders, Mads Hald Andersen, DMSc, PhD, Director of the National Center for Cancer Immune Therapy (CCIT-DK), chaired and presented at an educational session on cancer vaccines at the... Read More

Preclinical data further support the potential of dual-antigen and TGF-β-directed vaccines to reshape the tumor microenvironment and drive anti-tumor immunity NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced the presentation of new preclinical data for two vaccine... Read More

New non-clinical data strengthens evidence of contributions of IO102 and IO103 to tumor growth control through target specific T-cell activation, offering a distinct and complementary approach to checkpoint inhibitors New preclinical data for IO170 add to growing body of evidence supporting the potential of immune-modulatory therapeutic cancer vaccines to treat a wide range of cancers NEW YORK, March 25, 2025 (GLOBE... Read More

Biopharmaceutical company recognized for innovation in the development of immune-modulatory therapeutic cancer vaccines NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, has been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2025. Fast Company recognizes 609 organizations across 58 sectors and regions. IO Biotech has been... Read More

Preparations for submission of a Biologics License Application (BLA) for Cylembio ® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end 2025 remain on track. The trial completed enrollment in December 2023 ahead of plan with 407 patients. The primary endpoint of the pivotal Phase 3 trial is progression free survival (PFS); the rate of PFS events has slowed and the readout of the primary endpoint is now expected in... Read More

Findings support the development of a novel peptide vaccine targeting the immunosuppressive effects of Transforming Growth Beta (TGF-β) in solid tumors NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced details of its poster presentation at the American Association for... Read More

Presentation will include an update on the development and launch preparations of Cylembio™ (imsapepimut and etimupepimut, adjuvanted) NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that Mai-Britt Zocca, PhD, President and CEO, will present a company overview at... Read More

Submission of Investigational New Drug Application (IND) to US FDA expected in 2025 NEW YORK, Feb. 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced the publication of results from a preclinical study of its second immune-modulatory therapeutic cancer vaccine candidate, IO112,... Read More

Enrollment Completed Ahead of Schedule Initial Data Expected in 2025 NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, completed enrollment in its neoadjuvant/adjuvant Phase 2 basket trial (IOB-032/PN-E40). The trial is studying IO102-IO103, the company’s lead investigational... Read More

Funds expected to be used to advance IO Biotech’s immune-modulating therapeutic cancer vaccines, including potential BLA submission for IO102-IO103 in 2025 Commitment is part of the European Investment Bank’s strategy to support biotech companies with cutting-edge expertise in therapeutic areas such as immuno-oncology Debt facility expected to extend company’s cash runway into the second quarter of 2026 COPENHAGEN, Denmark... Read More

Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA ® (pembrolizumab) in patients with advanced melanoma on track with primary endpoint of progression free survival (PFS) projected to be reached in first half of 2025 Primary endpoint met in Phase 2 basket trial (IOB-022/KN-D38) cohort evaluating IO102-IO103 in... Read More

NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that members of its senior management team will participate in the following upcoming investor conferences: Event: Jefferies London Healthcare Conference Location: London One-on-one... Read More

Metastatic non-small cell lung cancer (NSCLC) patients treated in the first line setting with IO102-IO103 in combination with Keytruda ® demonstrated promising activity with an overall response rate of 55% unconfirmed/48% confirmed, disease control rate of 81%, and approximately 50% of patients without disease progression at 12 months; median duration of response not reached Safety profile consistent with prior studies with... Read More

NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win ® platform, today announced two abstracts accepted for poster presentation at the Society for Immunotherapy of Cancer’s 39th Annual Meeting (SITC 2024) taking place taking place in Houston, Texas on November 8-10,... Read More

Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head and Neck Cohort No New Safety Signals or Added Systemic Safety Concerns Observed Data Presented at the European Society for Medical Oncology (ESMO) Congress NEW YORK, Sept. 14, 2024 (GLOBE NEWSWIRE) -- I O Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company... Read More

Based on a per-protocol interim analysis of safety and efficacy data, the Independent Data Monitoring Committee (IDMC) recommended that the trial continue without modifications No new safety signals observed at interim analysis Primary endpoint of progression free survival projected to be reached in the first half of 2025 NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage... Read More

NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that members of its senior management team will provide a corporate update and participate in one-on-one meetings at the following upcoming investor conferences: Event: Morgan Stanley 22 nd Annual Global... Read More

Phase 3 interim analysis outcome still expected in Q3 2024 for the overall response rate (ORR) in the pivotal trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with Merck’s anti-PD-1 therapy KEYTRUDA ® (pembrolizumab) in patients with advanced melanoma; outcome of primary endpoint of progression free survival (PFS) expected in first half of 2025 Completed enrollment in... Read More

NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win ® platform, announced today that an abstract related to IO102-IO103, the company’s lead investigational therapeutic cancer vaccine candidate, has been accepted for poster presentation at the European Society for Medical Oncology... Read More

NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win ® platform, announced today that Mai-Britt Zocca, Ph.D., the company’s President and CEO, will be presenting, and both Dr. Zocca and Amy Sullivan, the company’s CFO, will be participating in one-on-one investor meetings at the... Read More

Outcome of interim analysis for the overall response rate (ORR) for the first 225 patients randomized in the pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with pembrolizumab still expected in Q3 2024; outcome of primary endpoint of progression free survival (PFS) is now projected to occur in first half of 2025 Completed enrollment in Phase 2 basket... Read More

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win ® platform, today announced the acceptance of an abstract related to IO102-IO103, the company’s lead investigational therapeutic cancer vaccine candidate, for presentation at the American Society of Clinical Oncology (ASCO) Annual... Read More

NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win ® platform, today announced that Marjan Shamsaei, PharmD, joined the company as SVP, Commercial Development and Portfolio Lead for IO102-IO103, the company’s lead cancer vaccine candidate currently in a pivotal Phase 3 trial. Ms.... Read More

NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win ® platform, today shared new data related to the company’s lead therapeutic cancer vaccine candidate, IO102-IO103, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San... Read More

NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win ® platform, today announced that Faiçal Miyara, Ph.D., has been appointed as the company’s chief business officer. Dr. Miyara, who has more than 17 years of experience in the pharmaceutical industry, will be responsible for global... Read More

New nonclinical data strengthen evidence of individual contribution of IO102 and IO103 in controlling tumor growth NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that an abstract has been accepted for presentation at the American Association for... Read More

Completed enrollment of pivotal Phase 3 trial of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA® (pembrolizumab), in patients with advanced melanoma; planned interim analysis for overall response rate (ORR) expected in third quarter of 2024 by independent data monitoring committee Progressed clinical development of IO102-IO103 with first patient dosed in Phase 2 basket trial of... Read More

NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, announced today that Mai-Britt Zocca, Ph.D., the company’s President and CEO, will be presenting, and both Dr. Zocca and Amy Sullivan, the company’s CFO, will be participating in one-on-one investor meetings at the 44 th... Read More

NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating therapeutic cancer vaccines based on its T-win ® platform, announced today that the first patient has been dosed in its Phase 2 trial (NCT05280314) studying treatment with IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA ® (pembrolizumab) in neoadjuvant and... Read More

Completed enrollment of 380 patients in pivotal Phase 3 trial of lead therapeutic cancer vaccine, IO102-IO103 in combination with KEYTRUDA ® (pembrolizumab), in patients with advanced melanoma Presented encouraging preliminary data from Phase 2 basket trial of IO102-IO103 at the IASLC 2023 World Conference on Lung Cancer (WCLC) in September 2023 and at the European Society of Medical Oncology (ESMO) annual meeting in October... Read More

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating cancer vaccines based on its T-win® technology platform, announced the appointment of Helen Collins, MD, to its board of directors. Dr. Collins is an industry veteran with significant experience in oncology/hematology drug development and will serve on the Research and... Read More

Trial expected to reach the primary endpoint of progression free survival in the second half of 2025 Per-protocol interim analysis expected in mid-2024 NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines, announced today that it has completed enrollment in the pivotal Phase 3 clinical trial for... Read More

NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win ® technology platform, today announced its participation in the upcoming investor conferences: Event: Jefferies London Healthcare Conference Location: London One-on-one meetings: Wednesday, November 15, 2023 Participants: Mai-Britt Zocca, PhD,... Read More

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating cancer vaccines based on its T-win ® technology platform, today announced three poster presentations at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC) being held in San Diego, California from November 1-5, 2023. “The data presented provide clear evidence... Read More

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines, announced encouraging preliminary data from the company’s Phase 2 basket trial of IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA ® (pembrolizumab) (IOB-022/KN-D38) at the ESMO Congress being held in Madrid from October 20-24,... Read More

NEW YORK, Oct. 03, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win ® technology platform, announced three poster presentations at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023), to be held in San Diego, California on November 1-5, 2023. Two of the posters will include new in vivo... Read More

Encouraging interim data support the potential of IO102-IO103 in combination with pembrolizumab as first-line treatment in non-small cell lung cancer NEW YORK, Sept. 12, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced that data from a pre-defined interim analysis related to the... Read More

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced its participation in the upcoming investor conferences: Event: Morgan Stanley 21 st Annual Global Healthcare Conference Location: New York, New York Fireside Chat Date & Time: Tuesday, September 12, 2023... Read More

Achieved significant enrollment milestone in pivotal Phase 3 trial of IO102-IO103 cancer vaccine in advanced melanoma; full enrollment anticipated by the end of 2023 Initiated enrollment in three investigator-initiated trials which the company is supporting to evaluate IO102-IO103 in combination regimens across a variety of cancer types Continued enrollment in Phase 2 basket trial of IO102-IO103, in patients with lung... Read More

NEW YORK, Aug. 11, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win ® technology platform, announced the appointment of Heidi Hunter to its board of directors. Ms. Hunter, an accomplished global biotech leader with over 25 years of experience across the pharmaceutical value chain, from clinical and commercial... Read More

NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today an abstract related to the company’s Phase 2 basket trial of IO102-IO103 as an investigational agent in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in solid tumors... Read More

Offering includes participation from both new and existing healthcare-dedicated investors Proceeds extend the company’s cash runway into the fourth quarter of 2025 NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- IO Biotech, Inc. (Nasdaq: IOBT), a clinical biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced that it has entered into a definitive... Read More

NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win ® technology platform, announced today that the University of California Davis Comprehensive Cancer Center has dosed the first patient in its investigator-initiated trial which aims to evaluate IO102-IO103, the company’s investigational... Read More

NEW YORK, July 25, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today an abstract related to the company’s Phase 2 basket trial (IOB-022/KN-D38) with IO102-IO103 as an investigational agent in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in solid... Read More

Eric Faulkner, currently Sr. Vice President, CMC, appointed as Chief Technical Officer NEW YORK, July 18, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced the appointment of Qasim Ahmad, MD, as Chief Medical Officer. Dr. Ahmad joins IO Biotech from Novartis, where he most... Read More

225 patients now randomized in global Phase 3 clinical trial for IO102-IO103, in combination with pembrolizumab, in patients with advanced melanoma; trial protocol calls for an interim analysis of overall response rate (ORR) one year after 225 patients have been randomized Data obtained from this analysis, if positive, could allow for submission of a Biologics License Application for accelerated approval in the United States... Read More

NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced today that biopharma executive Christine Richter joined the company as SVP, Commercial and Program Lead for IO102-IO103, the company’s lead cancer vaccine candidate. Dr. Richter will report to IO Biotech’s CEO,... Read More

NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced today that Mai-Britt Zocca, Ph.D., the company’s President and CEO, and Amy Sullivan, the company’s CFO, will be presenting and participating in one-on-one investor meetings at the Jefferies Healthcare Conference... Read More

The company expects to enroll 225 patients in its Phase 3 pivotal trial (IOB-013/KN-D18) in advanced melanoma by mid-2023 and to fully enroll the trial by the end of 2023. The Phase 3 trial protocol calls for an interim analysis of overall response rate (ORR) one year after 225 patients have been randomized; data obtained from this analysis could allow for submission of a Biologics License Application for an accelerated... Read More

Enrollment in the company’s Phase 3 pivotal trial (IOB-013/KN-D18) in advanced melanoma accelerated in the second half of 2022; the company expects to enroll 75% of patients by mid-2023 and fully enroll the trial by the end of 2023. The Phase 3 trial protocol calls for an interim analysis of overall response rate one year after 75% of patients have been randomized; this interim analysis could allow for submission of a... Read More

NEW YORK, Feb. 22, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® vaccine platform, today announced participation in two upcoming investor conferences. Mai-Britt Zocca, Ph.D., the company’s President and CEO, will participate in the Novel IO Panel at the Cowen 43rd Annual Health Care Conference, taking... Read More

NEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win ® vaccine platform, today announced the appointment of Devin Smith as the company’s first General Counsel and Chief Compliance Officer. Mr. Smith will oversee all company legal activities and provide strategic guidance and corporate... Read More

Independent data monitoring committee recommends that the company’s Phase 3 trial evaluating IO102-IO103 in combination with pembrolizumab in first-line advanced melanoma patients continue without any modifications; the trial is enrolling patients at more than 80 active sites globally. Encouraging initial data reported from 9 evaluable non-small cell lung cancer patients from the company’s ongoing Phase 2 solid tumor basket... Read More